ABBV-711 / AbbVie - LARVOL DELTA

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: AbbVie | Trial completion date: Apr 2029 ➔ Oct 2030

Adverse events • First-in-human • Monotherapy • Trial completion date • Squamous Cell Carcinoma

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • First-in-human • Monotherapy • Squamous Cell Carcinoma

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors (clinicaltrials.gov) - P1 | N=220 | Not yet recruiting | Sponsor: AbbVie

Adverse events • First-in-human • Monotherapy • New P1 trial • Squamous Cell Carcinoma